Fmr LLC Has $224,000 Stake in XBiotech Inc. (NASDAQ:XBIT)

Fmr LLC raised its stake in shares of XBiotech Inc. (NASDAQ:XBIT) by 34.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 28,992 shares of the biopharmaceutical company’s stock after acquiring an additional 7,420 shares during the quarter. Fmr LLC’s holdings in XBiotech were worth $224,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in XBIT. Rhumbline Advisers grew its position in XBiotech by 2,568.5% during the second quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 19,341 shares in the last quarter. American Century Companies Inc. bought a new stake in shares of XBiotech in the 2nd quarter worth approximately $393,000. Charles Schwab Investment Management Inc. lifted its position in shares of XBiotech by 7.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 58,437 shares of the biopharmaceutical company’s stock worth $452,000 after acquiring an additional 4,298 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of XBiotech by 102.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock worth $505,000 after purchasing an additional 49,863 shares in the last quarter. Institutional investors and hedge funds own 55.70% of the company’s stock.

XBiotech Trading Up 0.6 %

Shares of NASDAQ XBIT opened at $6.38 on Friday. The firm has a market capitalization of $194.48 million, a price-to-earnings ratio of -5.91 and a beta of 1.41. XBiotech Inc. has a one year low of $3.81 and a one year high of $9.96. The business has a fifty day simple moving average of $7.07 and a 200 day simple moving average of $6.68.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.